Decrease. In June 24th, the revenue was 4.99 billion yen (+7.3% year-on-year growth), operating profit was 0.827 billion yen (+3.0% year-on-year growth), and ordinary profit was 0.8 billion yen (0% year-on-year growth). In the future, the company will aim to expand its business scale through both the establishment of hospitals and business succession/M&A, and strengthen research and development activities for drug discovery and commodity related to animal medical care utilization of the clinical foundation possessed by the Group, and promote the creation of new sources of revenue other than clinical animal medical care, and it is expected that ordinary profit for the June 5th period will increase by 10.9% from the previous year to 0.888 billion yen, but buying precedes and the upward trend is heavy.